Spotlight on zanamivir in influenza

American Journal of Respiratory Medicine

Volumn 1, Issue 2, 2002, Pages 147-152

  Cheer, Susan M ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; INFLUENZA VACCINE; PARACETAMOL; PLACEBO; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIBIOTIC RESISTANCE; ASTHMA; BRONCHITIS; BRONCHOSPASM; CHILD CARE; CLINICAL TRIAL; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG USE; ELDERLY CARE; FATIGUE; HEADACHE; HIGH RISK PATIENT; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHALER; LIVER TOXICITY; LONG TERM CARE; LUNG FUNCTION; MALAISE; MUSCULOSKELETAL DISEASE; NAUSEA; NONHUMAN; NOSE DISEASE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SINUSITIS; SLEEP; SYMPTOMATOLOGY; THROAT DISEASE; TONSIL DISEASE; VERTIGO;

EID: 0041385603     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256603     Document Type: Review

References (51)

1. Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993 Jul; 37: 1473-9
2. von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993 Jun 3; 363: 418-23
3. Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994; 25: 123-31
4. Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998 Feb; 37: 107-20
5. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998 Mar; 42: 640-6
6. Gubareva LV, McCullers JA, Bethell RC, et al. Characterization of influenza A/Hongkong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 1998; 178: 1592-6
7. Ryan DM, Ticehurst J, Dempsey MH, et al. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994; 38: 2270-5
8. Fenton RJ, Morley PJ, Owens IJ, et al. Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract. Antimicrob Agents Chemother 1999 Nov; 43 (11): 2642-7
9. Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 1995; 39: 2583-4
10. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996 Jan; 275 (4): 295-9
11. Hayden FG, Lobo M, Hussey EK, et al. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. Brown LE, Hampson AW, Webster RG. Options for the control of influenza III. Amsterdam: Elsevier Science, 1996: 718-25
12. Gor D, Cadman A, Dempsey M, et al. Antiviral efficacy and sequence analysis of HA and NA genes of influenza isolates from zanamivir phase II/III clinical efficacy trials [abstract no. 284]. 39th ICAAC; 1999 Sep 26-29; San Francisco, CA, 421
13. Boivin G, Goyette N, Aoki F, et al. Clinical and virological efficacy of zanamivir in the treatment of influenza A virus infections during the 1997-98 flu season [abstract no. 289a.]. 39th ICAAC; 1999 Sep 26-29; San Francisco, CA, 423
14. Barnett JM, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000 Jan; 44 (1): 78-87
15. Daly J, Cadman A, Tisdale M, et al. Zanamivir and rimantadine susceptibility of virus isolates from a clinical trial comparing the use of zanamivir or rimantadine in the control of nursing home influenza outbreaks [abstract no. 181]. 40th ICAAC; 2000 Sep, 260
16. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000 Nov 2; 343 (18): 1282-9
17. Cass LMR, Gunawardena KA, Macmahon MM, et al. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med 2000 Feb; 94 (2): 166-73
18. Cass LMR, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 21-31
19. Peng AW, Hussey EK, Rosolowski B, et al. Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children. Curr Ther Res Clin Exp 2000; 61 (1): 36-46
20. Cass LMR, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 1-11
21. Cass LMR, Efthymiopoulos C, Marsh J, et al. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin Pharmacokinet 1999; 36 Suppl. 1: 13-9
22. Daniel MJ, Barnett JM, Pearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet 1999; 36 Suppl. 1: 41-50
23. Webster A, Boyce M, Edmundson S, et al. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 51-8
24. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874-80
25. MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-81
26. Lalezari J, Klein T, Stapleton J, et al. The efficacy and safety of inhaled zanamivir in the treatment of influenza in otherwise healthy and high risk individuals in North America [abstract P8]. J Antimicrob Chemother 1999; 44 Suppl. A: 42
27. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999 Nov; 44 Suppl. B: 23-9
28. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double- blind, placebo-controlled European study. J Infect 2000 Jan; 40 (1): 42-8
29. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999 Aug; 180: 254-61
30. Matsumoto K, Ogawa N, Nerome K, et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. Antiviral Ther 1999; 4: 61-8
31. Fleming DM, McCarthy TP, Keene O. An analysis of pooled efficacy data from phase III studies of zanamivir in the treatment of influenza. Eur Respir J Suppl 2000 Aug; 16 Suppl. 31: 18s
32. Osterhaus ADME, Hedrick JA, Henrickson KJ, et al. Clinical efficacy of inhaled zanamivir for the treatment of patients with influenza B virus infection: A pooled analysis of randomised, placebo-controlled studies. Clin Drug Invest 2000; 20 (4): 223-8
33. Monto AS, Moult AB, Sharp SJ. Effect of zanamivir on duration and resolution of influenza symptoms. Clin Ther 2000 Nov; 22 (11): 1294-305
34. Kaiser L, Keene ON, Hammond JM, et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000 Nov 27; 160 (21): 3234-40
35. Lalezari J, Elliott M, Keene O. The efficacy and safety of inhaled zanamivir in the treatment of influenza A and B in high risk individuals - results of phase II and III clinical studies [abstract no. P8]. 39th ICAAC; 1999 Sep 26, 420
36. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001 Jan 22; 161 (2): 212-7
37. Murphy KR, Eivindson A, Pauksens K, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Invest 2000; 20 (5): 337-49
38. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000 May; 19 (5): 410-7
39. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000 Nov; 21 (11): 700-4
40. McGeer AJ, Lee W, McArthur M, et al. Use of zanamivir to control an outbreak of influenza A in a nursing home. Clin Infect Dis 2000 Jul; 31: 318
41. Hirji Z, O'Grady S, Bonham J, et al. Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing-care population [in French]. Can Commun Dis Rep Health Canada 2001 Feb 1; 27 (3): 21-4
42. Gravenstein S, Drinka P, Osterweil D, et al. A multicenter prospective double-blind randomized controlled trial comparing the relative safety and efficacy of zanamivir to rimantadine for nursing home influenza outbreak control [abstract no. 1155]. 40th ICAAC; 2000 Sep, 270
43. Freund B, Gravenstein S, Elliott M, et al. Zanamivir: a review of clinical safety. Drug Saf 1999 Oct; 21 (4): 267-81
44. Gravenstein S, Johnston SL, Loeschel E, et al. A review of clinical safety in high risk subjects. Drug Saf 2001 Nov; 24 (15): 1-10
45. Armstrong EP, Khan ZM, Perry AS, et al. Zanamivir vs oseltamivir: which drug is more cost-effective? [reply]. Formulary 2001 May; 36: 384-7
46. et al. Brady B, McAuley L, Shukla VK. Economic evaluation of zanamivir for the treatment of influenza. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 2001; Technology Report no. 13: 1-63
47. National Institute for Clinical Excellence. Zanamivir for the treatment of influenza in adults [online]. Available from URL: http://www.nice.org.uk/pdf/zanamivirtreatment.pdf [Accessed 2001 Oct 16]
48. Mauskopf JA, Cates SC, Griffin AD, et al. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 2000 Jun; 17 (6): 611-20
49. Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics 2001; 19 (3): 293-301
50. Glaxo Wellcome. Relenza. (zanamivir for inhalation): US prescribing information. USA: Glaxo Wellcome, 2001
51. Glaxo Wellcome. Relenza: Summary of product characteristics. UK: Glaxo Wellcome, 2001